EGFR and neoplasm: As shown in Figure 2, the competitive anti-EGFR monoclonal antibody C225 could significantly reduce the binding of EBP-Gd-DO3A and EBP-(Gd-DO3A)3 to EGFR, leading to decreased cellular Gd levels of both conjugates in tumor cells.